AUM Biosciences will be presenting at the BIO CEO & Investor Conference.
New York, 11 – 12 February 2019
AUM Biosciences will be presenting at the BIO CEO & Investor Conference, one of the largest biotech investor conferences to be held in New York on the 11th and 12th February 2019. We are excited to be part of this important healthcare meeting.
Details about the event can be found here: https://www.bio.org/events/bio-ceo-investor-conference
For more information, please contact email@example.com
About AUM Biosciences
AUM Biosciences (AUM) is an oncology-focused Asian biotechnology company committed to developing affordable cancer therapies. Dedicated to unlocking the value in innovation, AUM harnesses the power of precision medicine and digital health to support patients, physicians and partners. AUM focuses on earlystage development of innovative treatment of cancers prevalent in Asia with the potential to address global markets.
AUM develops potent and highly selective therapeutics in oncology, with an aim to change the drug development paradigm by implementing a holistic approach to developing drugs. AUM Biosciences is led by a highly-experienced management team with over 75 years of high-quality oncology drug development experience combined.
Headquartered in Singapore, AUM is strategically positioned to work, partner and collaborate with leading research institutes, clinicians and pharmaceutical companies globally. AUM is the recipient of Frost & Sullivan’s 2019 Asia-Pacific Biotech Entrepreneurial Company of the Year. For more information, please visit www.aumbiosciences.com